AddedRisk Factors
and financial resources, expose us to product liability or other claims, harm our reputation with customers and adversely impact our business, financial condition and results of operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
adverse effect on our business. Any of the foregoing may cause us to incur substantial costs, and could place a significant strain on our financial resources, divert the attention of management from our core business and harm our reputation.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
In addition, we may need to obtain additional licenses from our existing licensors and others to allow commercialization of products we may develop. Moreover, we may be required to expend significant time and resources to
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedRisk Factors
Section 404 of the Sarbanes-Oxley Act requires that we maintain effective internal control over financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluations, document our controls
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedRisk Factors
and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
reduced Medicare payments to several categories of healthcare providers, including hospitals, and increased the statute of limitations period for the government to recover Medicare overpayments to providers from three to five years.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
Initiating and completing clinical trials necessary to support any future PMA applications or de novo requests, or to provide additional safety and efficacy data beyond those typically required for a 510(k) clearance, for our possible future
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
We rely in part on our portfolio of issued patents and pending patent applications in the United States and other countries to protect our intellectual property and competitive position. However, our patent applications may not result in issued patents, and any patents that are issued may not provide meaningful protection against competitors or competitive technologies. Further, the examination process may require us to narrow the claims for our pending patent applications, which may limit the scope of patent protection that may be obtained if these applications issue. It is also possible that we
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedRisk Factors
will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. These provisions may also result in increased costs for investors seeking to bring a claim against us or any of our directors, officers or other employees.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedRisk Factors
As supervisory authorities issue further guidance on personal data export mechanisms, including circumstances where the SCCs cannot be used, and/or start taking enforcement action, we could suffer additional costs, complaints and/or regulatory investigations or fines, and/or if we are otherwise unable to transfer personal data between and among countries and regions in which we operate, it could affect the manner in which we provide our services, the geographical location or segregation of our relevant systems and operations, and could adversely affect our financial results.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
The intellectual property laws and other statutory and contractual arrangements in the United States and other jurisdictions we depend upon may not provide sufficient protection in the future to prevent the infringement, use, violation or misappropriation of our patents, trademarks, data, technology and other intellectual property rights, products and services, and may not provide an adequate remedy if our intellectual property rights are infringed, misappropriated or otherwise violated. violated, including in connection with our use of AI, as intellectual property protection in the field of AI is evolving and there is uncertainty regarding the degree and extent of protection that may be available for AI technologies and related system inputs and outputs.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If the FDA disagrees with our determination and requires us to submit new 510(k) notifications or PMA applications for modifications to our previously cleared products for which we have concluded that new clearances or approvals are unnecessary, we may be required to cease marketing or to recall the modified product until we obtain clearance or approval, and we may be subject to significant regulatory fines or penalties.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Moreover, as a result of the broad scale release and availability of Artificial Intelligence (AI) technologies such as generative AI, there There is a global trend towards more regulation of AI technologies (e.g., the EU AI Act and AI laws passed in U.S. states) to ensure the ethical use, privacy, and security of AI and the data that it processes.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
If we fail to maintain necessary marketing authorizations for our robotic systems, or if approvals or clearances for future products or modifications to existing products are delayed or not issued, it will negatively affect our business, financial condition and results of operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any provision of our amended and restated certificate of incorporation currently in effect or Delaware law that has the effect of delaying or deterring a change in control could limit the opportunity for our stockholders to receive a premium for their shares of our common stock, and could also affect the price that some investors are willing to pay for our common stock.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
We rely on a combination of contractual provisions, confidentiality procedures and patent, trade secret, copyright and trademark laws to protect our proprietary technology, products, services, brands, trade secrets, know-how and data and prevent others from duplicating our robotic systems or its disposable components, and our other current and future products, services and technology.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
A loss of key personnel or their work product could hamper or prevent our ability to commercialize our product, which could have an adverse effect on our business, financial condition and results of operations.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any person or entity purchasing or otherwise acquiring any interest in our shares of capital stock shall be deemed to have notice of and consented to this exclusive forum provision, but will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Any Moreover, any change in the laws or regulations pursued by the current presidential administration and Congress that govern the clearance and approval processes relating to our current and future products products, including with respect to FDA regulations, could make it more difficult and costly to obtain clearance or approval for new products, or to produce, market and distribute existing products.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Class II devices are subject to the FDA’s General Controls, and special controls as deemed necessary by the FDA to ensure the safety and effectiveness of the device.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedRisk Factors
Current and future legislative and regulatory proposals to further reform healthcare or reduce healthcare costs may limit coverage of or lower reimbursement for the procedures associated with the use of our products.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The provision for income taxes consists primarily of foreign income taxes, as the Company does not have U.S. federal or state taxable income for the periods presented. As we expand the scale of our international business activities, any changes in the United States and foreign taxation of such activities may increase our overall provision for income taxes in the future. We have a valuation allowance for our United States deferred tax assets, including federal and state non-operating loss carryforwards. We expect to maintain this valuation allowance until it becomes more likely than not that the benefit of our federal and state deferred tax assets will be realized by way of expected future taxable income in the United States.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
•the costs associated with a regulatory or government action or other litigation;
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
The Term Loan Facility is scheduled to mature on October 6, 2027, the fifth anniversary of the closing date, or the Maturity Date. We have the option to prepay the Term Loan Facility without any prepayment charge or fee.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
AddedMD&A
In August 2025, we entered into a second amendment to the loan and security agreement (the “Second Amendment”), which, among other things, modified the repayment terms such that the entire principal amount outstanding is now due on the Maturity Date, replacing the prior repayment schedule of interest-only payments followed by monthly principal amortization payments. After giving effect to the Second Amendment, we are obligated to maintain in collateral accounts held at the lender (a) if our cash and cash equivalents is less than $50.0 million, 100% of our cash and cash equivalents; or (b) if our cash and cash equivalents is greater than or equal to $50.0 million, the greater of (i) $50.0 million or (ii) 50% of our cash and cash equivalents, with amounts exceeding $50.0 million permitted to be held outside of the lender in collateral accounts managed by the lender.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RemovedMD&A
any stock exchange on which our securities are traded, investor relations, and other administrative and professional services expenses, though it may fluctuate from quarter to quarter. However, over time, we expect our SG&A expenses to decrease as a percentage of revenue.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
Loss on loan extinguishment was a result of our acquisition price of our new debt exceeded the carrying amount of our existing debt during the fiscal year ended December 31, 2022.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
We completed a follow-on offering of common stock in October 2024, which raised $164.5 million in proceeds to us, net of issuance costs. Previously, our primary sources of capital have been from our initial public offering, private placements of redeemable convertible preferred securities and debt financing agreements.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
The term loan facility is scheduled to mature on October 6, 2027, the fifth anniversary of the Closing Date (the “Maturity Date”). The loan and security agreement provides for interest-only payments on the term loan facility for the first thirty-six months following the Closing Date (the “Initial Interest-Only Period”). The Initial Interest-Only Period will be extended to an additional twelve months if we achieve either (i) $200.0 million or greater in revenue in any twelve-month period or (ii) $0 or greater in EBITDA in any six-month period. Thereafter, amortization payments on the Term Loan Facility will be payable monthly until the Maturity Date in monthly installments equal to 20% of the then outstanding principal amount of the Term Loan Facility divided by 12 plus any accrued and unpaid interest. We have the option to prepay the Term Loan Facility without any prepayment charge or fee. We achieved the twelve-month revenue target as of December 31, 2024.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
period of the immediately preceding year. If we maintain at least $100.0 million in available cash, then it is not required to meet such financial covenants.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RemovedMD&A
We have determined that our obligation to pay success fees to a lender upon a successful liquidation event or achieving a revenue target represents freestanding financial instruments. The instrument is classified as a current liability in the consolidated balance sheets and is subject to remeasurement at each consolidated balance sheet date. Any change in fair value is recognized through other income (expense) in the consolidated statements of operations and comprehensive loss. We adjust the carrying values of the loan facility derivative liability for changes in fair value and will continue to do so until the earlier of cash payment or expiration. The assumptions used in determining the fair value of the obligation require significant judgment.
Read it in 10-K Feb 27, 2025 at sec.govopen_in_new
RewordedMD&A
During the year ended December 31, 2024, 2025, net cash provided by financing activities was $180.1 $11.2 million, consisting primarily of proceeds of $4.8 million from the exercise of stock options and proceeds of $6.4 million from the issuance of common stock of $164.5 million, net of issuance costs, and proceeds of $11.1 million from under the exercise of employee stock options. purchase plan.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Cost of sales increased $22.3 $24.4 million, or 34%, 28%, to $111.8 million during the year ended December 31, 2025, compared to $87.4 million during the year ended December 31, 2024, compared to $65.1 million during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
R&D expenses increased $13.9 $9.0 million, or 29%, 14%, to $71.3 million during the year ended December 31, 2025, compared to $62.3 million during the year ended December 31, 2024, compared to $48.4 million during the year ended December 31, 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Operating activities $ (48,985) $ (99,213) $ (108,003) $ (80,382) Investing activities (9,356) (4,409) (25,206) (2,653) Financing activities 11,193 180,125 167,795 3,612 Effect of exchange rates on cash, cash equivalents and restricted cash (74) — — Net increase (decrease) in cash, cash equivalents and restricted cash $ (47,222) $ 76,503 $ 34,586 $ (79,423)
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
However, over time, we expect our R&D expenses to decrease as a percentage of revenue to vary over time depending on the level and timing of initiating new product development efforts. revenue.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in interest and other income, net was primarily due to higher an increase in average cash balances during the year, partially offset by decreases in interest rates earned on our cash equivalents. rates.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The increase in R&D expenses was primarily due to employee-related expenses from increased headcount of our R&D organization, organization such as well as increases in third-party product development costs. salaries and wages and stock-based compensation.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
Interest expense of $4.2 $3.6 million during the year ended December 31, 2024 remained relatively flat 2025 decreased $0.6 million or 14% compared to fiscal 2023. 2024.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
The expansion of our commercialization activities resulted in increases in inventory, accounts receivable, prepaid expenses and other current assets along with long-term assets, a decrease in accounts payable, partially offset by an increase in accrued compensation, deferred revenue, lease other accrued liabilities, and accrued interest expense.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
In the United States, we are initially focused on driving adoption of Aquablation therapy among urologists that perform hospital-based resective BPH surgery.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
We expect our R&D expenses to increase in absolute dollars for the foreseeable future as we make strategic investments in R&D, continue to develop, develop and enhance and commercialize new existing products and technologies, though it may fluctuate from quarter to quarter.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
RewordedMD&A
In the United States, we are initially focused on driving adoption of Aquablation therapy among urologists that perform hospital-based resective BPH surgery.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new
Quiet changesMD&A
Selling, general and administrative, or SG&A, expenses include consist primarily of compensation for personnel, including stock-based compensation, related to selling, marketing, clinical affairs, professional education, finance, information technology, and human resource functions.
Read it in 10-K Feb 26, 2026 at sec.govopen_in_new